Doctors

Research Studies at ECHN

Interested in participating in a research study? Please call the Research office at ECHN, (860) 646-2518.

Many physicians on the ECHN medical staff participate in research studies, also called clinical trials, which test new medications or procedures. Patients may choose to participate in such trials as a way to have access to some newer treatments and as a way to contribute to medical science.

A research study involving human subjects is not conducted unless a medication or procedure is deemed safe enough to use for humans. All studies at ECHN must be approved by the ECHN Institutional Review Committee.

ECHN physicians join leading researchers from around the world in working to bring the latest, leading-edge treatments to market. Here is a list of research studies currently underway at ECHN:

*Eisai Protocol 501-CL-003: A Phase 2 Double Blind, Randomized, Dose-Ranging, Placebo-Controlled, Parallel Group Study of AKR-501 Tablets Taken Orally Once Daily for 28 Days in Patients with Chronic Idiopathic Thrombocytopenic Purpura (ITP)

Stephen H. Grund, MD

*Eisai Protocol 501-CL-004: A Phase 2 Parallel Group, Rollover Study of AKR-501 in Patients with Chronic Idiopathic Thrombocytopenic Purpura (ITP) Who Completed 28 Days of Study Treatment in Protocol 501-CL-003

Stephen H. Grund, MD

*Amgen Protocol 20050232: A Randomized, Double Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of AMG 531 Treatment of Subjects with Low or Intermediate Risk Myelodysplastic Syndrome (MDS) Receiving Hypomethylating Agents

Michael A. Reale, MD

Amgen Protocol 20060197: An Open Label Extension Study Evaluating the Safety in Long Term Dosing of Romiplostim (formerly AMG 531) in Thrombocytopenic Subjects with Myelodysplastic Syndrome (MDS)

Michael A. Reale, MD

*ECOG PACCT-1, Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment: The TAILORx Trial

Jeffrey S. Wasser, MD

*E1602, A Randomized Phase II Trial of Multi-Epitope Vaccination with Melanoma Peptides for Cytotoxic T Cells and Helper T Cells for Patients with Metastatic Melanoma

Jeffrey S. Wasser, MD

*E2Z04, Quality of Life in Younger Breast Cancer Survivors

Jeffrey S. Wasser, MD

*E2805, A Randomized Double Blind Phase III Trial of Adjuvant Sunitinib versus Sorafenib versus Placebo in Patients with Resected Renal Cell Carcinoma

Jeffrey S. Wasser, MD

*E4805, A Randomized Phase II Study to Determine the Effect of Two Different Doses of AVE0005 (VEGF Trap) in Patients with Metastastic Renal Cell Carcinoma

Jeffrey S. Wasser, MD

*E5805, A Phase II Trial of E7389 (Halicondrin B Analog) in Patients with Metastatic Hormone Refractory Prostate Cancer

Jeffrey S. Wasser, MD

*Genentech, AVF3991n, An Observational Study of Avastin® (Bevacizumab) in Combination with Chemotherapy for Treatment of Metastatic or Locally Advanced and Unresectable Colorectal Cancer, Locally Advanced or Metastatic Non-small Cell Lung (Excluding Predominant Squamous Cell Histology), or Locally Recurrent or Metastatic Breast Cancer

Dr. Michael Reale

*JMA.17, A Phase III, Randomized Double-Blind Study of Letrozole versus Placebo in Women with Primary Breast Cancer Completing Five or More Years of Adjuvant Tamoxifen & JMA17.R

Jeffrey S. Wasser, MD

*Ligand Protocol L4665-03: A phase IIA Randomized Double Blind, Placebo-Controlled Study of the Efficacy and Safety of LGD4665 in Patients with Immune Thrombocytopenic Purpura (ITP) with an Open Label Extension

Jeffrey S. Wasser, MD

*N0147, A Randomized Phase III Trial of Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/ Leucovorin (CF) with or without Cetuximab (C225) after Curative Resection for Patients with Stage III Colon Cancer

Jeffrey S. Wasser, MD

*Novartis protocol CSTI5721BUS227, Gastrointestinal Stromal Tumors (GIST) Registry Protocol

Jeffrey S. Wasser, MD

Updated 2/17/09